Danielle Pillsbury

Case Study

QSP 建模优化多发性骨髓瘤疗法的首次人体试验剂量选择

Multiple myeloma, the second most common blood cancer, affects an estimated 160,000 individuals annually worldwide…

Danielle Pillsbury2025 年 3 月 25 日

Case Study

Quantitative systems pharmacology model of mRNA lipid nanoparticle for two programs at the preclinical to clinical transition

This case study features Applied BioMath's* collaboration with Alexion Pharmaceuticals. Alexion Pharmaceuticals, Inc. is a…

Danielle Pillsbury2025 年 3 月 25 日

Blog

Centers of Excellence in Pharma: Driving Efficiency and Innovation

2025 年 3 月 25 日 In today's fast-paced pharmaceutical industry, Centers of Excellence (CoEs) have become vital…

Danielle Pillsbury2025 年 3 月 25 日

eBook

Transform Drug Development with Certara’s Medical Writing Expertise

The cost of developing a single drug exceeds $2.6 billion, and the demand for life-saving…

Danielle Pillsbury2025 年 3 月 24 日

Webinar

Unleashing the Power of Patents: Competitive Analysis in Material Science [Korean webinar]

日期：2025 年 4 月 16 日, 星期三时间：3pm – 4pm, Korea timeSolutions: DiscoveryServices: Drug Development ServicesProducts: ChemaxonThis…

Danielle Pillsbury2025 年 3 月 21 日

Publication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…

Danielle Pillsbury2025 年 3 月 20 日

Announcement

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

RADNOR, PA – 2025 年 3 月 18 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…

Danielle Pillsbury2025 年 3 月 19 日

On-Demand Webinar

Phoenix Hosted: 基于云的 PK/PD 软件可实现更智能、更快速的研究

In this on demand webinar, you’ll discover why Phoenix Hosted is the ideal solution for…

Danielle Pillsbury2025 年 3 月 19 日

Announcement

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

2025 年 3 月 17 日 Radnor, PA – – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…

Danielle Pillsbury2025 年 3 月 17 日

Brochure

Libra product overview

Discover Libra, the innovative tool that transforms DILI prediction in early drug discovery. By optimizing…

Danielle Pillsbury2025 年 3 月 14 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Danielle Pillsbury

QSP 建模优化多发性骨髓瘤疗法的首次人体试验剂量选择

Quantitative systems pharmacology model of mRNA lipid nanoparticle for two programs at the preclinical to clinical transition

Centers of Excellence in Pharma: Driving Efficiency and Innovation

Transform Drug Development with Certara’s Medical Writing Expertise

Unleashing the Power of Patents: Competitive Analysis in Material Science [Korean webinar]

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

Phoenix Hosted: 基于云的 PK/PD 软件可实现更智能、更快速的研究

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

Libra product overview

订阅时事通讯

快捷链接

解决方案

联系我们